On May 15th, 2019, Carsten Thiel was announced as the President Europe while Darrel Cohen became the head of Clinical Development. Both appointees bring extensive experience to the firm aimed at growing the EUSA commercial infrastructure. EUSA Pharma is a global biopharmaceutical firm that develops medicines to treat rare diseases. Therefore, it was necessary to strengthen the top management with the new appointees. Dr. Carsten Thiel holds a Ph.D. in Molecular Biology and brings 27 years of experience of commercial pharmaceuticals gained from several companies. Before joining EUSA, Carsten Thiel was the CEO of a gene therapy specialist based in the US. Dr. Thiel also served as the Chief Commercial Officer at Alexion Pharmaceuticals Inc that deal with a rare disease.
Additionally, Carsten Thiel held a top position at EMEA an Australasia and Asia Pacific organizations. He headed the European Amgen company before joining EMEA. And another leading position at European oncology franchise company. Dr. Thiel started his career at Hoffmann La-Roche. According to Carsten Thiel that EUSA Pharma has a strong foundation in oncology and rare disease business. Moreover, the firm possess a compelling portfolio that will enable the firm to achieve its ambitious plan. EUSA Pharma has made a great stride in their commercial operations, especially in the United States and Europe.
EUSA Pharma hires experienced management team such as Carsten Thiel and Darrel Cohen, who have a clean record of building successful companies. The firm is expanding its market across the globe, and Dr. Thiel experience in international roles helps the company meet its objectives. EUSA supports their leaders by providing funding to complete the various projects. The most funds are raised from EW Healthcare Partners, who are the leading investors in life science. Carsten Thiel sees the appointment as an excellent opportunity to lead the expansion of EUSA commercialization activities.
To know more click: here.